- $910.44m
- $408.14m
- $24.05m
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial
Alumis' lupus drug fails mid-stage trial goal
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
Alumis Inc. reports results for the quarter ended June 30 - Earnings Summary
Alumis Q1 revenue drops, net loss narrows after trial completion
Brief: Alumis Q1 Operating Expenses USD 100.15 Million
Brief: Alumis Announces Late-Breaker Oral Presentation Of Phase 3 Data For Envudeucitinib In Moderate-To-Severe Plaque Psoriasis At 2026 American Academy Of Dermatology Annual Meeting
U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap
U.S. STOCKS ON THE MOVE-Bloom Energy, Tyson Foods, Voyager Technologies
U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike
Biopharma firm Alumis rises after boosted $300 mln stock sale
Brief: Alumis Announces Pricing Of Upsized Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
U.S. STOCKS ON THE MOVE-Netflix, Alumis, Micron Technology
Biopharma firm Alumis extends gains after commencing $175 mln stock offering
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology